real-time news and commentary for investors
Monday, Oct 22
2012, 1:38 PM
Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite SUPN)...
Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age.